Lucaparib Tablets 200 mg and 300 mg: Product Information, Uses, Strengths and FAQs

Lucaparib Tablets – Product Overview

Lucaparib is a prescription oncology medicine containing rucaparib, an active ingredient belonging to the poly (ADP-ribose) polymerase (PARP) inhibitor class. It is used under specialist medical supervision for certain types of cancer, depending on the patient's diagnosis, treatment history and applicable prescribing guidelines.

For healthcare professionals, pharmacists and authorised pharmaceutical procurement teams researching Lucaparib tablets, understanding the product's composition, available strengths and prescribing requirements is essential before sourcing or dispensing this medicine.

Important formulation note: Available product listings identify Lucaparib as an oral tablet. It should not be described or marketed as an injection unless the exact injectable product, active ingredient and approved product documentation have been independently verified.

Lucaparib Composition and Available Strengths

Lucaparib tablets are listed in the following strengths:

Lucaparib 200 mg Tablets: Contains rucaparib 200 mg per tablet.

Lucaparib 300 mg Tablets: Contains rucaparib 300 mg per tablet.

The marketed formulation and strength should always be confirmed against the manufacturer's packaging and current product documentation. These strengths refer to tablets, not injectable presentations.

What Is Lucaparib Used For?

Rucaparib is a targeted anticancer medicine prescribed for certain ovarian, fallopian tube, primary peritoneal and prostate cancers, subject to the applicable approved indication and patient eligibility criteria.

Rucaparib works by inhibiting PARP enzymes, which play a role in repairing damaged DNA. In susceptible cancer cells, blocking this repair pathway can contribute to cancer-cell death.

Treatment decisions depend on factors such as cancer type, previous treatment, relevant biomarker or genetic testing, and the applicable prescribing information. Lucaparib is not suitable for every patient with cancer and should only be used under the direction of a qualified oncology specialist.

Key Product Information

Brand name: Lucaparib

Active ingredient: Rucaparib

Therapeutic category: Antineoplastic medicine

Drug class: PARP inhibitor

Dosage form: Oral tablets

Listed strengths: 200 mg and 300 mg

Route of administration: Oral

Prescription status: Prescription medicine

Product specifications, pack sizes, storage conditions and market authorisations should be verified using current manufacturer documentation before publication or procurement.

Safety Information and Precautions

Lucaparib may cause adverse effects, including nausea, fatigue, reduced appetite, anaemia, gastrointestinal symptoms and changes in liver-function tests. Serious blood-related complications may also occur.

Patients should undergo the monitoring recommended by their oncology team, including appropriate blood tests. Before treatment, they should disclose all medicines they take, existing medical conditions and any pregnancy or breastfeeding considerations to their healthcare professional.

The medicine must be taken exactly as prescribed. Patients should not change the dose, discontinue treatment or substitute another oncology medicine without consulting their treating specialist.

This product information is intended for general educational purposes and does not replace professional medical advice or the approved prescribing information.

Frequently Asked Questions About Lucaparib

1. What is the active ingredient in Lucaparib?

Lucaparib tablets contain rucaparib, a targeted anticancer medicine classified as a PARP inhibitor.

2. Which strengths of Lucaparib are available?

Product listings identify Lucaparib 200 mg and 300 mg tablets. Confirm current availability and specifications with the authorised supplier.

3. Is Lucaparib available as an injection?

The product listings reviewed identify Lucaparib as an oral tablet. An injectable formulation should not be assumed to exist without verified product documentation.

4. What cancers may be treated with rucaparib?

Rucaparib is prescribed for certain ovarian, fallopian tube, primary peritoneal and prostate cancers, depending on the applicable indication and patient eligibility.

5. Is Lucaparib available without a prescription?

Lucaparib is a prescription oncology medicine. It should be obtained and used through appropriate authorised channels under medical supervision.

6. Where can healthcare buyers verify Lucaparib product details?

Healthcare professionals and authorised procurement teams should consult the manufacturer, current product literature and relevant national regulatory authority for verified specifications and supply information.

Product Information and Enquiries

For accurate Lucaparib product information, verify the dosage form, strength, packaging, regulatory status and authorised supply arrangements before placing an order. Any product enquiry or procurement request should comply with the regulations.